Last 12 months
Inside the activity.
0 purchase rows · 33 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 3 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2024 Filed Feb 21, 2024 22:40 UTC |
Parisi Samuel JosephVP, Finance (Interim PAO)
|
Exercise / conversionOrdinary Shares | 2,034 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006175 · form4.xml · nonDerivative · entry 1 Parisi Samuel Joseph · CIK 0002010945 · VP, Finance (Interim PAO) 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:33 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 8,897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006171 · form4.xml · derivative · entry 5 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,793 Underlying: Ordinary Shares · 8,897 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:33 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
Tax withholdingOrdinary Shares | 3,888 | $32.18 | $125,115.84 |
DisclosureSEC source: 0001127602-24-006171 · form4.xml · nonDerivative · entry 2 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,954 Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:33 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
Exercise / conversionOrdinary Shares | 8,897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006171 · form4.xml · nonDerivative · entry 1 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:32 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 8,897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006170 · form4.xml · derivative · entry 5 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,793 Underlying: Ordinary Shares · 8,897 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:32 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Tax withholdingOrdinary Shares | 3,951 | $32.18 | $127,143.18 |
DisclosureSEC source: 0001127602-24-006170 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,883 Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:32 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Exercise / conversionOrdinary Shares | 8,897 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006170 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:30 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 6,355 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006169 · form4.xml · derivative · entry 5 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,709 Underlying: Ordinary Shares · 6,355 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:30 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
Tax withholdingOrdinary Shares | 1,869 | $32.18 | $60,144.42 |
DisclosureSEC source: 0001127602-24-006169 · form4.xml · nonDerivative · entry 2 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,193 Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:30 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
Exercise / conversionOrdinary Shares | 6,355 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006169 · form4.xml · nonDerivative · entry 1 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:27 UTC |
Brown Iain MichaelSVP, Chief Financial Officer
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 6,355 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006168 · form4.xml · derivative · entry 5 Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,709 Underlying: Ordinary Shares · 6,355 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:27 UTC |
Brown Iain MichaelSVP, Chief Financial Officer
|
Tax withholdingOrdinary Shares | 1,869 | $32.18 | $60,144.42 |
DisclosureSEC source: 0001127602-24-006168 · form4.xml · nonDerivative · entry 2 Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,199 Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 22:27 UTC |
Brown Iain MichaelSVP, Chief Financial Officer
|
Exercise / conversionOrdinary Shares | 6,355 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-006168 · form4.xml · nonDerivative · entry 1 Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:01 UTC |
LAURENCIN CATO TDirector
|
Exercise / conversionNon Qualified Stock Option (Right to Buy) · Derivative | 2,690 | $0.00 Strike: $22.52 | $0.00 |
DisclosureSEC source: 0001127602-24-005339 · form4.xml · derivative · entry 3 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,833 Underlying: Ordinary Shares · 2,690 shares Expires 2031-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. F2 · derivative.exercise_date: Shares subject to the stock option award vest in three equal annual installments commencing on 12/8/2022. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:01 UTC |
LAURENCIN CATO TDirector
|
SaleOrdinary Shares | 2,690 | $31.85 | $85,676.50 |
DisclosureSEC source: 0001127602-24-005339 · form4.xml · nonDerivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,169 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:01 UTC |
LAURENCIN CATO TDirector
|
Exercise / conversionOrdinary Shares | 2,690 | $22.52 | $60,578.80 |
DisclosureSEC source: 0001127602-24-005339 · form4.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 2/26/2023. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 22:11 UTC |
MCKEON BRIAN PDirector
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 4,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · derivative · entry 11 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · derivative.exercise_date: This award is fully vested in accordance with its terms. F5 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 22:11 UTC |
MCKEON BRIAN PDirector
|
Tax withholdingOrdinary Shares | 1,088 | $27.32 | $29,724.16 |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · nonDerivative · entry 2 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,141 Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 22:11 UTC |
MCKEON BRIAN PDirector
|
Exercise / conversionOrdinary Shares | 4,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004741 · form4.xml · nonDerivative · entry 1 MCKEON BRIAN P · CIK 0001219445 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 22:07 UTC |
Daglio David Angelo Jr.Director
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 4,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004738 · form4.xml · derivative · entry 11 Daglio David Angelo Jr. · CIK 0001837109 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · derivative.exercise_date: This award is fully vested in accordance with its terms. F5 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 22:07 UTC |
Daglio David Angelo Jr.Director
|
Tax withholdingOrdinary Shares | 1,088 | $27.32 | $29,724.16 |
DisclosureSEC source: 0001127602-24-004738 · form4.xml · nonDerivative · entry 2 Daglio David Angelo Jr. · CIK 0001837109 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,141 Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 22:07 UTC |
Daglio David Angelo Jr.Director
|
Exercise / conversionOrdinary Shares | 4,533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004738 · form4.xml · nonDerivative · entry 1 Daglio David Angelo Jr. · CIK 0001837109 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 03:00 UTC |
POPS RICHARD FDirector · Director and CEO, Alkermes plc
|
Tax withholdingOrdinary Shares | 91,757 | $26.77 | $2,456,334.89 |
DisclosureSEC source: 0001127602-24-004634 · form4.xml · nonDerivative · entry 2 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,179,675 Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 03:00 UTC |
POPS RICHARD FDirector · Director and CEO, Alkermes plc
|
GrantOrdinary Shares | 218,551 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004634 · form4.xml · nonDerivative · entry 1 POPS RICHARD F · CIK 0001126490 · Director · Director and CEO, Alkermes plc 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,271,432 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:59 UTC |
Nichols Christian ToddSVP, Chief Commercial Officer
|
Tax withholdingOrdinary Shares | 8,135 | $26.77 | $217,773.95 |
DisclosureSEC source: 0001127602-24-004633 · form4.xml · nonDerivative · entry 2 Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,806 Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:59 UTC |
Nichols Christian ToddSVP, Chief Commercial Officer
|
GrantOrdinary Shares | 27,012 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004633 · form4.xml · nonDerivative · entry 1 Nichols Christian Todd · CIK 0001813312 · SVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,941 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:58 UTC |
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.
|
Tax withholdingOrdinary Shares | 3,183 | $26.77 | $85,208.91 |
DisclosureSEC source: 0001127602-24-004631 · form4.xml · nonDerivative · entry 2 LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,744 Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:58 UTC |
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.
|
GrantOrdinary Shares | 21,485 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004631 · form4.xml · nonDerivative · entry 1 LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,927 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:57 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
Tax withholdingOrdinary Shares | 15,280 | $26.77 | $409,045.60 |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · nonDerivative · entry 2 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,937 Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:57 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
GrantOrdinary Shares | 46,658 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · nonDerivative · entry 1 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,217 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:56 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
Tax withholdingOrdinary Shares | 8,483 | $26.77 | $227,089.91 |
DisclosureSEC source: 0001127602-24-004629 · form4.xml · nonDerivative · entry 2 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,707 Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:56 UTC |
Gaffin David JosephEVP, CLO, Alkermes, Inc.
|
GrantOrdinary Shares | 28,240 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004629 · form4.xml · nonDerivative · entry 1 Gaffin David Joseph · CIK 0001675905 · EVP, CLO, Alkermes, Inc. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,190 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:55 UTC |
Brown Iain MichaelSVP, Chief Financial Officer
|
Tax withholdingOrdinary Shares | 8,137 | $26.77 | $217,827.49 |
DisclosureSEC source: 0001127602-24-004628 · form4.xml · nonDerivative · entry 2 Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,713 Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:55 UTC |
Brown Iain MichaelSVP, Chief Financial Officer
|
GrantOrdinary Shares | 27,012 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004628 · form4.xml · nonDerivative · entry 1 Brown Iain Michael · CIK 0001643456 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,850 F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 22:02 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
Tax withholdingOrdinary Shares | 11,007 | $26.77 | $294,657.39 |
DisclosureSEC source: 0001127602-24-004729 · form4.xml · nonDerivative · entry 2 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,945 F1 · date: Late filing due to administrative error. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 22:02 UTC |
Jackson Blair CurtisEVP, Chief Operating Officer
|
GrantOrdinary Shares | 36,835 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004729 · form4.xml · nonDerivative · entry 1 Jackson Blair Curtis · CIK 0001842348 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,952 F1 · date: Late filing due to administrative error. F2 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 01:46 UTC |
LAURENCIN CATO TDirector
|
Exercise / conversionRestricted Stock Unit Award · Derivative | 4,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 9 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,163 Underlying: Ordinary Shares · 4,163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F8 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. F8 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 01:46 UTC |
LAURENCIN CATO TDirector
|
Tax withholdingOrdinary Shares | 1,000 | $25.86 | $25,860.00 |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · nonDerivative · entry 2 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,169 Read SEC document |
| December 08, 2023 Filed Dec 13, 2023 01:46 UTC |
LAURENCIN CATO TDirector
|
Exercise / conversionOrdinary Shares | 4,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · nonDerivative · entry 1 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| November 17, 2023 Filed Dec 13, 2023 01:46 UTC |
LAURENCIN CATO TDirector
|
OtherRestricted Stock Unit Award · Derivative | 163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 8 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,326 Underlying: Ordinary Shares · 163 shares Expires not disclosed F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F8 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. F8 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. Read SEC document |
| November 17, 2023 Filed Dec 13, 2023 01:46 UTC |
LAURENCIN CATO TDirector
|
OtherRestricted Stock Unit Award · Derivative | 119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 7 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,104 Underlying: Ordinary Shares · 119 shares Expires not disclosed F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Dec 13, 2023 01:46 UTC |
LAURENCIN CATO TDirector
|
OtherNon Qualified Stock Option (Right to Buy) · Derivative | 254 | $30.72 Strike: $30.72 | $7,801.86 |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 6 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,986 Underlying: Ordinary Shares · 254 shares Expires 2033-06-29 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F6 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Dec 13, 2023 01:46 UTC |
LAURENCIN CATO TDirector
|
OtherNon Qualified Stock Option (Right to Buy) · Derivative | 231 | $30.86 Strike: $30.86 | $7,129.35 |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 5 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,785 Underlying: Ordinary Shares · 231 shares Expires 2032-07-07 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F5 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Dec 13, 2023 01:46 UTC |
LAURENCIN CATO TDirector
|
OtherNon Qualified Stock Option (Right to Buy) · Derivative | 422 | $22.52 Strike: $22.52 | $9,503.44 |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 4 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,523 Underlying: Ordinary Shares · 422 shares Expires 2031-12-08 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_date: Shares subject to the stock option award vest in three equal annual installments commencing on 12/8/2022. Read SEC document |
| November 17, 2023 Filed Dec 13, 2023 01:46 UTC |
LAURENCIN CATO TDirector
|
OtherNon Qualified Stock Option (Right to Buy) · Derivative | 112 | $22.52 Strike: $22.52 | $2,522.24 |
DisclosureSEC source: 0001127602-23-029515 · form4.xml · derivative · entry 3 LAURENCIN CATO T · CIK 0001444810 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,712 Underlying: Ordinary Shares · 112 shares Expires 2031-12-08 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
OtherRestricted Stock Unit Award · Derivative | 603 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 13 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,757 Underlying: Ordinary Shares · 603 shares Expires not disclosed F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F12 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. F12 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
OtherEmployee Stock Option (Right to Buy) · Derivative | 2,412 | $26.82 Strike: $26.82 | $64,689.84 |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 12 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,027 Underlying: Ordinary Shares · 2,412 shares Expires 2033-02-23 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F11 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
OtherRestricted Stock Unit Award · Derivative | 523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 11 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,690 Underlying: Ordinary Shares · 523 shares Expires not disclosed F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F10 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. F10 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
OtherEmployee Stock Option (Right to Buy) · Derivative | 2,790 | $24.59 Strike: $24.59 | $68,606.10 |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 10 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,344 Underlying: Ordinary Shares · 2,790 shares Expires 2032-02-18 F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F9 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023. Read SEC document |
| November 17, 2023 Filed Feb 13, 2024 02:57 UTC |
Hopkinson Craig C.EVP R&D, Chief Medical Officer
|
OtherRestricted Stock Unit Award · Derivative | 481 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-004630 · form4.xml · derivative · entry 9 Hopkinson Craig C. · CIK 0001730048 · EVP R&D, Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,557 Underlying: Ordinary Shares · 481 shares Expires not disclosed F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F8 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022. F8 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.